The price of Myovant Sciences Ltd. (NYSE:MYOV) shares last traded on Wall Street fell -0.11% to $26.93.
MYOV stock price is now 0.79% away from the 50-day moving average and 53.22% away from the 200-day moving average. The market capitalization of the company currently stands at $2.61B.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
On August 09, 2022, SVB Leerink Upgraded its previous ‘Mkt Perform’ rating to ‘Outperform’ on the stock increasing its target price from $12 to quote $23, while ‘Goldman’ rates the stock as ‘Neutral’.
In other news, Mehra Uneek, Principal Financial Officer sold 2,241 shares of the company’s stock on Dec 16. The stock was sold for $59,947 at an average price of $26.75. Upon completion of the transaction, the Principal Financial Officer now directly owns 202,696 shares in the company, valued at $5.46 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 18, Chief Commercial Officer Merendino Lauren sold 1,703 shares of the business’s stock. A total of $42,916 was realized by selling the stock at an average price of $25.20. This leaves the insider owning 171,546 shares of the company worth $4.62 million. Insiders disposed of 164,143 shares of company stock worth roughly $4.42 million over the past 1 year. A total of 1.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MYOV stock. A new stake in Myovant Sciences Ltd. shares was purchased by POLAR CAPITAL HOLDINGS PLC during the first quarter worth $52,457,000. INVESCO LTD. invested $5,442,000 in shares of MYOV during the first quarter. In the first quarter, VOLORIDGE INVESTMENT MANAGEMENT, LLC acquired a new stake in Myovant Sciences Ltd. valued at approximately $3,480,000. JUMP FINANCIAL, LLC acquired a new stake in MYOV for approximately $2,426,000. SQUAREPOINT OPS LLC purchased a new stake in MYOV valued at around $2,270,000 in the second quarter. In total, there are 145 active investors with 31.60% ownership of the company’s stock.
A candlestick chart of Myovant Sciences Ltd. (NYSE: MYOV) showed a price of $26.94 on Tuesday morning. During the past 12 months, Myovant Sciences Ltd. has had a low of $7.67 and a high of $27.02. The fifty day moving average price for MYOV is $26.72 and a two-hundred day moving average price translates $17.58 for the stock.
The latest earnings results from Myovant Sciences Ltd. (NYSE: MYOV) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.47, beating analysts’ expectations of -$0.49 by 0.02. This compares to -$0.23 EPS in the same period last year. The net profit margin was -56.90% and return on equity was 39.90% for MYOV. The company reported revenue of $104.82 million for the quarter, compared to $77.9 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 34.56 percent. For the current quarter, analysts expect MYOV to generate $102.36M in revenue.
Myovant Sciences Ltd.(MYOV) Company Profile
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women’s health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
